Despite the lack of data from clinical trials targeting CCR2 in patients with cardiovascular disease, studies in experimental models of atherosclerosis have provided supportive evidence for an atheroprotective effect of pharmacologically targeting CCR2 [13]. This evidence concerns the gene CCR2 and cardiovascular disorder.